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HDL-C and LDL-C of 1.51 (P  0.02) and 1.02 (P  0.02). Alternatively, a 1% 
increase in HDL-C equates to a 1.5% change in cardiovascular events while a 1% 
reduction in LDL-C equates to a 1% reduction in those events. HDL-C is statistically 
signiﬁcantly inversely related to mortality. Higher HDL-C is associated with a decrease 
in the likelihood of death (1.73; P  0.04) while repeated measures that are higher 
further decrease that probability (0.01: P  0.02). Lower LDL-C decreases the 
probability of death. CONCLUSIONS: The relationship between HDL-C and all-
cause mortality was quantiﬁed, replicated and validated and shown to be of greater 
prognostic value than LDL-C.
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OBJECTIVES: Approximately 230,000 percutaneous coronary interventions (PCIs) 
were performed in the Germany in 2005. PCI complications often increase resource 
utilization. New antithrombotic therapies have the potential to improve outcomes and          
decrease costs. The ACUITY and HORIZONS-AMI studies demonstrated improved 
clinical event rates (mortality and bleeding) using bivalirudin compared to a heparin-
plus-GPI regimen. This analysis evaluated the economic impact of this improvement 
in the German hospital setting. METHODS: A budget-impact model was developed 
to evaluate the impact of bivalirudin in unstable angina (UA)/non-ST-elevated myo-
cardial infarction (NSTEMI) patients undergoing PCI in a German hospital. Clinical 
data for the model were derived from the ACUITY trial and included 30-day event 
rates for major complications (major and minor bleeding as deﬁned by trial protocol, 
Q-wave myocardial infarction, repeat PCI and coronary artery bypass graft [CABG]). 
Economic data were derived from the medical literature, including clinical outcomes 
as well as ward costs (both regular and ICU/CCU) and pharmaceutical costs. Addi-
tional analysis using resource use data from the ADONIS registry was performed. A 
subgroup of high risk patients (per ESC deﬁnition) was also examined in the model. 
RESULTS: For UA/NSTEMI patients, overall average per procedure cost was a5347 
with heparin plus GPI and a4822 with bivalirudin. In 100 PCI patients, bivalirudin 
use would result in 3 fewer major bleeding events (3.1%) and 11 fewer minor bleeding 
events (10.7%). Total hospital costs comparing 100% heparin-based strategy to 100% 
bivalirudin-based strategy were a341,473 and a289,025, respectively, resulting in a 
cost-savings with bivalirudin of a52,448 (15%). For high risk UA/NSTEMI patients 
the cost-savings over 100 procedures are a56,233 (16%). CONCLUSIONS: A bivali-
rudin-based strategy for anticoagulant use in UA/NSTEMI patients undergoing PCI is 
associated with favorable clinical and economic outcomes when compared with 
heparin plus GPI in a German hospital setting.
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OBJECTIVES: Preeclampsia, a leading cause of maternal and perinatal morbidity and 
mortality, is only detected after the onset of clinical symptoms. Earlier diagnosis may 
be possible with a new serum test using soluble fms-like tyrosine kinase-1 (sFlt-1) and 
placental growth factor (PlGF) biomarkers. Clinical and economic beneﬁts may result 
from appropriate detection and management of subclinical cases, and from averting 
costs associated with incorrect diagnoses. We evaluated the ﬁnancial impact of the 
novel test versus standard care from a German health care payer perspective. 
METHODS: We developed a decision-analytic model of the clinical and economic 
impact resulting from improved sensitivity and speciﬁcity of the new test over current 
diagnostic practice. Acute management and follow-up costs were associated with true 
positive, true negative, false positive, and false negative diagnoses. The base-case 
analysis assumed that, of all pregnant women, 10% present with risk factors while 
90% do not. The CHF 52 (a-equivalent) test was assumed to be administered after 
20 weeks of gestation. True positive and false negative patients were assumed to enter 
one of four health states: mild preeclampsia; severe preeclampsia; eclampsia; or death. 
Data pertaining to treatment practices, health care resource utilization, incidence, 
costs, and funding for detection and management of preeclampsia in Germany were 
obtained through interviews with clinicians, laboratory managers, and health care 
payers in Germany. Additional data were obtained from published literature and 
public databases. RESULTS: Model results suggest that when used for screening, the 
novel test would reduce false negative diagnoses of preeclampsia by 67% and false 
positives by 71%. Costs per patient are estimated to be a941 with the novel test and 
a1578 with standard practice, saving an estimated a637 per patient given the novel 
test. CONCLUSIONS: This test has the potential to improve detection and manage-
ment of preeclampsia translating into substantial cost savings for German health care 
payers.
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OBJECTIVES: Approximately 5900 PPCIs were performed in the UK in 2007. This 
number is expected to double in the next 5 years post the 2008 NIAP report. New 
antithrombotic therapies have the potential to improve clinical outcomes and decrease 
costs. The HORIZONS-AMI study of bivalirudin demonstrated reduced clinical event 
rates (mortality and bleeding) compared to a heparin and GPI (HEPGPI) regimen. 
The potential economic value of implementing bivalirudin in the PPCI setting is evalu-
ated in this analysis from the UK hospital perspective. METHODS: A budget impact 
model was developed to compare treatment of STEMI patients undergoing PPCI with 
either bivalirudin or HEPGPI. Clinical data for the model was derived from the 
HORIZONS trial, and included 30-day event rates for major complications (major 
and minor bleeding as deﬁned by trial protocol, Q-wave myocardial infarction [MI], 
and repeat PCI and coronary artery bypass graft [CABG] procedures). UK cost and 
clinical practice data were derived from published sources. RESULTS: Overall average 
procedure cost per bivalirudin-treated patient (incorporating 7.2% provisional GPI 
use as per HORIZONS) was £4284, compared to £5015 per HEPGPI-treated patient. 
In extrapolating these beneﬁts to a typical NHS hospital of 200 PPCI patients per 
year, 7 major bleeding events (3.4%), 13 minor bleeding events (6.6%), and 2 deaths 
(1%) in patients would be averted if treated with bivalirudin. The total hospital budget 
impact of treating 200 PPCI patients using a HEPGPI based strategy is £1,002,913. 
Introducing a bivalirudin-based strategy could save £146,129 (15%) per year. CON-
CLUSIONS: Using a bivalirudin-based strategy in STEMI patients undergoing PPCI 
is associated with favorable clinical and economic outcomes when compared with 
HEPGP in a UK hospital setting.
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OBJECTIVES: Due to a lack of awareness of Transient Ischaemic Attack (TIA) 
symptoms, many patients may not immediately seek medical help, creating a delay in 
access to treatment. The UK EXPRESS study by Rothwell et al. (Lancet 2007;370:1432–
42) demonstrated that greater focus on effectively managing TIA could have a signiﬁ-
cant impact on subsequent stroke rates. With nearly 200,000 strokes occurring in Italy 
each year, we wanted to examine how a shift in care pathways towards that outlined 
in phase 2 of the EXPRESS study could affect rates of stroke, and explore the ﬁnancial 
implications of such a shift in care pathway. METHODS: We developed an economic 
model to estimate the costs and savings associated with establishing a rapid assessment 
and treatment clinic for patients with suspected TIA in Italy, in line with phase 2 of 
the EXPRESS study. We used a population of 1,000,000 people with an assumed 
annual incidence of TIA of 0.058%. Current management was based on ESO guide-
lines and common clinical practice. We included direct costs associated with care 
(medications, diagnostics and staff—where data were unavailable, UK converted costs 
were used), and modelled the impact of changing management over three years. 
RESULTS: For a population of 1,000,000, changing the pathway of care to ensure 
rapid assessment and treatment for TIA patients would result in 180 future stroke 
events being avoided over three years. As a result, additional costs associated with 
changing the TIA pathway of care were offset by savings generated through avoiding 
acute stroke management costs. CONCLUSIONS: Our model suggests that imple-
menting a revised TIA care pathway in Italy would be cost saving. For a local popula-
tion of 1,000,000, savings associated with the avoidance of acute stroke management 
would offset the costs of establishing rapid assessment and treatment clinics for 
patients experiencing TIA.
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OBJECTIVES: Due to lack of awareness of Transient Ischaemic Attack (TIA) symp-
toms, many patients may not immediately seek medical help, creating a delay in access 
to treatment. The UK EXPRESS study by Rothwell et al. (Lancet 2007;370:1432–42) 
demonstrated that greater focus on rapid assessment and management of TIA could 
signiﬁcantly reduce subsequent stroke rates. With over 42,000 hospitalisations due to 
strokes in Hungary each year, we wanted to examine how a shift in care pathways 
towards that outlined in the EXPRESS study could affect stroke rates, and explore 
the ﬁnancial implications of such a shift in care pathway. METHODS: We developed 
an economic model to estimate the costs and savings associated with establishing a 
rapid assessment and treatment clinic for patients with suspected TIA in Hungary, in 
line with phase 2 of the EXPRESS study. We used a population of 1,000,000 with an 
assumed annual TIA incidence of 0.042%. Current management was based on ESO 
guidelines and common clinical practice. We included direct costs associated with 
secondary care (medications, diagnostics and staff—where data were unavailable, 
converted UK costs were used), and modelled the impact of changing management 
over a three-year time horizon. RESULTS: For a population of 1,000,000, changing 
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the care pathway to ensure rapid assessment and treatment for TIA patients would 
avoid 128 future stroke events over three years. As a result, the costs associated with 
the reconﬁguration of the TIA patient care pathway would be partially offset by 
savings in acute stroke management costs. CONCLUSIONS: Our model suggests that 
implementing a revised TIA care pathway in Hungary would result in a reduction of 
TIA-related recurrent strokes, leading to reduced costs associated with the acute 
management of stroke. This would partially offset the costs of establishing rapid 
assessment and treatment clinics for patients experiencing TIA.
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OBJECTIVES: Preeclampsia, a leading cause of maternal and perinatal morbidity 
and mortality, is only detected after the onset of clinical symptoms. Earlier diagnosis 
may be possible with a new serum test using soluble fms-like tyrosine kinase-1 (sFlt-1) 
and placental growth factor (PlGF) biomarkers. Clinical and economic beneﬁts may 
result from appropriate detection and management of subclinical cases, and from 
averting costs associated with incorrect diagnoses. We evaluated the ﬁnancial impact 
of the novel test versus standard care from a UK health care payer perspective. 
METHODS: We developed a decision-analytic model of the clinical and economic 
impact resulting from improved sensitivity and speciﬁcity of the new test over current 
diagnostic practice. Acute management and follow-up costs were associated with 
true positive, true negative, false positive, and false negative diagnoses. The base- 
case analysis assumed that, of all pregnant women, 15% present with risk factors 
while 85% do not. The CHF 52 (£-equivalent) test was assumed to be administered 
after 20 weeks of gestation. True positive and false negative patients were assumed 
to enter one of four health states: mild preeclampsia; severe preeclampsia; eclampsia; 
or death. Data pertaining to treatment practices, health care resource utilization, 
incidence, costs, and funding for detection and management of preeclampsia in the 
UK were obtained through interviews with clinicians, laboratory managers, and health 
care payers in the UK. Additional data were obtained from published literature and 
public databases. RESULTS: Model results suggest that when used for screening, the 
novel test would reduce false negative diagnoses of preeclampsia by 67% and 
false positives by 71%. Costs per patient are estimated to be £1781 with the novel 
test and £2726 with standard practice, saving an estimated £945 per patient given the 
novel test. CONCLUSIONS: This test has the potential to improve detection and 
management of preeclampsia translating into substantial cost savings for UK health 
care payers.
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OBJECTIVES: Due to lack of awareness of Transient Ischaemic Attack (TIA) symp-
toms, many patients may not immediately seek medical help, creating delay in access 
to treatment. The UK EXPRESS study by Rothwell et al. (Lancet 2007;370:1432–42) 
demonstrated that a greater focus on rapid assessment and management of TIA could 
signiﬁcantly reduce subsequent stroke rates. With nearly 35,000 cerebrovascular 
disease-related deaths in Spain last year, we wanted to examine how a shift in care 
pathways towards that outlined in the EXPRESS study could affect stroke rates, 
and explore the ﬁnancial implications of such a shift in care pathway. METHODS: 
We developed an economic model to estimate the costs and savings associated 
with establishing a rapid assessment and treatment clinic for patients with suspected 
TIA in Spain, in line with phase 2 of the EXPRESS study. We used a population     
of 1,000,000 people with an assumed annual incidence of TIA of 0.021%. 
Current management was based on ESO guidelines and common clinical practice. 
We included direct costs associated with care (medications, diagnostics and staff—
where data were unavailable, converted UK costs were used), and modeled the    
 impact of changing management over a three-year time horizon. RESULTS: For an 
assumed population of 1,000,000, changing the care pathway care to ensure rapid    
assessment and treatment for TIA patients would result in 66 future stroke events    
avoided over 3 years. As a result, the costs associated with changing the pathway of 
care for TIA would be partially offset by savings in acute management costs associated     
with stroke. CONCLUSIONS: Our model suggests that implementing a revised TIA 
care pathway in Spain would reduce the number of TIA-related recurrent strokes, 
leading to reduced costs associated with acute stoke management. This would partially 
offset the cost of establishing rapid assessment and treatment clinics for patients 
experiencing TIA.
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OBJECTIVES: Syncope that remains unexplained after a conventional evaluation is a 
common and vexing medical problem. Implantable loop recorder (ILR) is a new 
diagnostic method in diagnosis of recurrent syncope with unexplained etiology (NO). 
The aim of this analysis was to estimate the impact of ILR reimbursement in NO 
diagnostics on budget of public payer’s in Poland. METHODS: The analysis was 
performed in 5-year time horizon from the public payer’s perspective. Information 
regarding target population and medical resources was extracted from literature and 
registry PL-US. Data in the registry PL-US were collected during 2006–2008 in 18 
Polish centers. Cost data were obtained from the National Health Fund. In the analysis 
two scenarios were compared: actual (current situation with ILR reimbursement only 
in special cases) and prognostic (after ILR reimbursement). In the prognostic scenario 
two ﬁnancing options of monitoring of patients after ILR implantation were distin-
guished—AOS and KAOS. One-way sensitivity analysis were performed for the key 
input parameters. RESULTS: The number of target population for ILR implantation 
in Poland is stable, approximately 2370 patients. In actual scenario estimated annual 
public payer expenditure for NO diagnostics in each year 2010–2014 is approximately 
9.00 mPLN, where cost of ILR is 0.25 mPLN. Assuming reimbursement of ILR esti-
mated public payer expenditure for NO diagnostics in option AOS is 9.77 mPLN in 
year 2010 and 16.76 mPLN in year 2014, where ILR costs is 1.44 mPLN and 
11.34 mPLN, respectively. In option KAOS public payer expenditure is 9.86 mPLN 
in year 2010 and 18.49 mPLN in year 2014, where ILR costs is 1.53 mPLN and 
13.07 mPLN, respectively. CONCLUSIONS: Our ﬁndings suggest that decision con-
cerning ILR reimbursement should not lead to increase total expenses on the NO 
diagnostics for public payer more than 0.95 mPLN in year 2010 and 10.00 mPLN in 
year 2014.
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OBJECTIVES: Budget impact models for new drugs provide estimates of the changes 
in annual costs of drug therapy as well as estimates in the changes in other health care 
costs attributable to the underlying disease or the side effects of treatment. METHODS: 
In this study we estimated the annual change in disease and side-effects costs associated 
with the addition of prasugrel to a drug formulary for treatment of those with acute 
coronary syndrome (ACS) undergoing a percutaneous coronary intervention in a 
managed care organization with 1,000,000 covered lives. The model compared the 
annual costs in each of the ﬁrst three years after addition of prasugrel to the formulary 
assuming a maximum treatment share of 50% after 1 year. The only alternative treat-
ment was clopidogrel and people already being treated with clopidogrel were not 
switched to prasugrel. The relative risk of subsequent cardiovascular events and bleed-
ing events for each drug were taken from a head-to-head 15-month clinical trial. The 
risk of cardiovascular events reverted to the risk of those taking only aspirin for those 
discontinuing prasugrel or clopidogrel treatment. RESULTS: The estimated numbers 
of cardiovascular events (bleeding events) after an ACS episode with prasugrel on the 
formulary in the ﬁrst three years were 541 (36), 528 (42), and 525 (43) respectively 
and without prasugrel were 548 (35) in all three years. The annual reductions in 
disease- and bleeding-related costs in the ﬁrst 3 years after adding prasugrel to the 
formulary were estimated to be $141,907, $419,377, and $488,119 respectively. 
CONCLUSIONS: Using a more effective dual oral antiplatelet regimen is likely 
to result in lower disease-related costs that are not offset by higher bleeding-related 
costs. The disease- and bleeding-event cost savings estimated in the model should be 
included in a comprehensive estimate of the budget impact of adding prasugrel to a 
formulary.
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OBJECTIVES: Atrial ﬁbrillation (AF) is frequent cardial disease. The prevalence in 
Slovak republic is estimated about 1% in adult population. The most potential risk of 
AF is stroke, Ist incidence is estimated about 2.3% e.g. more than six times as in stan-
dard population. The main objective of this study was to determine direct medical costs 
related to AF and the possible budget impact of new treatment by dronedaron. 
METHODS: Direct medical costs were evaluated from data collected in 2007 from the 
General Health Insurance Company, the largest one in Slovakia, covering 55% of 5.4 
million inhabitants. The results were recalculated to the total population. The costs 
were quoted in 2007 prices. RESULTS: The AF costs were a16,685,720; in out-patients 
care they were a1,384,743; in hospital care they were a12,135,196; in drug consump-
tion they were a2,013,127 and in diagnostic procedures they were a1,152,653. Totally 
it was 0,556% of total Slovakia health care budget. The cost of treating the patients 
with stroke was a30,098,891, which is 1.003% of total Slovakia health care budget. 
Dronedaron is new drug for the treatment of AF. The outcomes from the ATHENA 
study showed 26% risk reduction of hospitalization and 34% risk reduction of stroke. 
The dronedaron usage can reduce the health care costs by a2,872,370 per year, i.e. 
0.096% from total budget. CONCLUSIONS: The direct costs associated with AF 
comprise an important part of total health care budget in Slovakia. They signalize 
